Key clinical point: The overall risk for serious infections was low in patients with psoriatic arthritis (PsA) who were new users of targeted therapies, with etanercept and ustekinumab being safer treatment options than adalimumab.
Major finding: The incidence of serious infections in new users of targeted therapies was 17.0 per 1000 person-years. Compared with new users of adalimumab, the risk for serious infections was significantly lower in new users of etanercept (weighted hazard ratio [wHR] 0.72; 95% CI 0.53-0.97) and ustekinumab (wHR 0.57; 95% CI 0.35-0.93).
Study details: This cohort study included 12,071 patients with PsA (age ≥ 18 years) from the French National Health Insurance Database who were new users of targeted therapies (adalimumab, etanercept, golimumab, certolizumab pegol, infliximab, secukinumab, ixekizumab, ustekinumab, and tofacitinib).
Disclosures: This study did not receive any specific funding. Two authors declared receiving meeting support, consulting fees, etc., from or having other ties with various sources. The other authors declared no conflicts of interest.
Source: Bastard L, Claudepierre P, Penso L, et al. Risk of serious infection associated with different classes of targeted therapies used in psoriatic arthritis: A nationwide cohort study from the French Health Insurance Database (SNDS). RMD Open. 2024;10:e003865 (Mar 14). doi: 10.1136/rmdopen-2023-003865 Source